Please login to the form below

Not currently logged in
Email:
Password:

dexamethasone

This page shows the latest dexamethasone news and features for those working in and with pharma, biotech and healthcare.

Triplet approvals for myeloma boost Celgene in Q2

Triplet approvals for myeloma boost Celgene in Q2

Revlimid gained on the back of its recent approval alongside Takeda’s Velcade (bortezomib) and dexamethasone as a first-line therapy for adults with multiple myeloma who are not eligible for

Latest news

  • CHMP backs Bayer’s tumour-agnostic drug Vitrakvi CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

    Squibb got the go-ahead for Empliciti (elotuzumab) alongside Celgene’s Pomalyst (pomalidomide) and dexamethasone for relapsed/refractory multiple myeloma, based on the ELOQUENT-3 trial.

  • FDA verdict on Sanofi’s Darzalex rival is due in April 2020 FDA verdict on Sanofi’s Darzalex rival is due in April 2020

    prolong progression-free survival (PFS) when added to a standard myeloma regimen of Celgene’s Pomalyst/Imnovid (pomalidomide) and low-dose dexamethasone. ... Empliciti picked up an additional approval from the FDA as a third-line therapy for myeloma in

  • Setback for Takeda as Ninlaro flunks amyloidosis trial Setback for Takeda as Ninlaro flunks amyloidosis trial

    Ninlaro (ixazomib) plus dexamethasone failed to achieve a significant increase in overall haematological response compared to physician’s choice treatment in the TOURMALINE-AL1 trial, which involved patients with relapsed or

  • After discount row, NICE finally says yes to first line Revlimid After discount row, NICE finally says yes to first line Revlimid

    However Revlimid still not the first choice in these patients: in its final draft guidance, published today, NICE recommends Revlimid in combination with dexamethasone as an option for previously untreated myeloma ... In a second piece of final draft

  • Janssen looks to expand Darzalex in Europe Janssen looks to expand Darzalex in Europe

    Those patients were directly compared to a group taking Revlimid and dexamethasone (Rd) alone, and results showed that at a median follow-up of 28 months, the Darzalex regimen significantly reduced ... Sanofi also has a promising CD38-targeting antibody

More from news
Approximately 4 fully matching, plus 90 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics